1-6 of 6
Angeles Alvarez Secord
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis

Amanda N. Fader, Dana M. Roque, Eric Siegel, Natalia Buza, Pei Hui, Osama Abdelghany, Setsuko Chambers, Angeles Alvarez Secord, Laura Havrilesky, David M. O'Malley, Floor J. Backes, Nicole Nevadunsky, Babak Edraki, Dirk Pikaart, William Lowery, Karim ElSahwi, Paul Celano, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, Alessandro D. Santin
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (15): 3928–3935.
https://doi.org/10.1158/1078-0432.CCR-20-0953
Published: 03 August 2020
View article titled, Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis
Open the PDF for Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis in another window
Includes: Supplementary data
Journal Articles

Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218

Angeles Alvarez Secord, Kirsten Bell Burdett, Kouros Owzar, David Tritchler, Alexander B. Sibley, Yingmiao Liu, Mark D. Starr, J. Chris Brady, Heather A. Lankes, Herbert I. Hurwitz, Robert S. Mannel, Krishnansu S. Tewari, David M. O'Malley, Heidi Gray, Jamie N. Bakkum-Gamez, Keiichi Fujiwara, Matthew Boente, Wei Deng, Robert A. Burger, Michael J. Birrer, Andrew B. Nixon
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (6): 1288–1296.
https://doi.org/10.1158/1078-0432.CCR-19-0226
Published: 13 March 2020
View article titled, Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218
Open the PDF for Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218 in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Amit M. Oza, Ursula A. Matulonis, Angeles Alvarez Secord, John Nemunaitis, Lynda D. Roman, Sarah P. Blagden, Susana Banerjee, William P. McGuire, Sharad Ghamande, Michael J. Birrer, Gini F. Fleming, Merry Jennifer Markham, Hal W. Hirte, Diane M. Provencher, Bristi Basu, Rebecca Kristeleit, Deborah K. Armstrong, Benjamin Schwartz, Patricia Braly, Geoff D. Hall, Kenneth P. Nephew, Simone Jueliger, Aram Oganesian, Sue Naim, Yong Hao, Harold Keer, Mohammad Azab, Daniela Matei
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (5): 1009–1016.
https://doi.org/10.1158/1078-0432.CCR-19-1638
Published: 02 March 2020
View article titled, A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Open the PDF for A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses

Daniela Matei, Sharad Ghamande, Lynda Roman, Angeles Alvarez Secord, John Nemunaitis, Merry Jennifer Markham, Kenneth P. Nephew, Simone Jueliger, Aram Oganesian, Sue Naim, Xiang Yao Su, Harold Keer, Mohammad Azab, Gini F. Fleming
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (10): 2285–2293.
https://doi.org/10.1158/1078-0432.CCR-17-3055
Published: 14 May 2018
View article titled, A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses
Open the PDF for A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer

Angeles Alvarez Secord, Deanna K. Teoh, William T. Barry, Miao Yu, Gloria Broadwater, Laura J. Havrilesky, Paula S. Lee, Andrew Berchuck, Johnathan Lancaster, Robert M. Wenham
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5489–5498.
https://doi.org/10.1158/1078-0432.CCR-12-0507
Published: 30 September 2012
View article titled, A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer
Open the PDF for A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Microarray Analysis of Early Stage Serous Ovarian Cancers Shows Profiles Predictive of Favorable Outcome

Andrew Berchuck, Edwin S. Iversen, Jingqin Luo, Jennifer P. Clarke, Hisani Horne, Douglas A. Levine, Jeff Boyd, Miguel A. Alonso, Angeles Alvarez Secord, Marcus Q. Bernardini, Jason C. Barnett, Todd Boren, Susan K. Murphy, Holly K. Dressman, Jeffrey R. Marks, Johnathan M. Lancaster
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (7): 2448–2455.
https://doi.org/10.1158/1078-0432.CCR-08-2430
Published: 01 April 2009
View article titled, Microarray Analysis of Early Stage Serous Ovarian Cancers Shows Profiles Predictive of Favorable Outcome
Open the PDF for Microarray Analysis of Early Stage Serous Ovarian Cancers Shows Profiles Predictive of Favorable Outcome in another window
Includes: Supplementary data